story of the week
Ibrutinib Plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
N. Engl. J. Med 2022 Jun 03;[EPub Ahead of Print], ML Wang, W Jurczak, M Jerkeman, J Trotman, PL Zinzani, D Belada, C Boccomini, IW Flinn, P Giri, A Goy, PA Hamlin, O Hermine, JÁ Hernández-Rivas, X Hong, SJ Kim, D Lewis, Y Mishima, M Özcan, GF Perini, C Pocock, Y Song, SE Spurgeon, JM Storring, J Walewski, J Zhu, R Qin, T Henninger, S Deshpande, A Howes, S Le Gouill, M DreylingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.